Skip to main content

Invus — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

104
Companies
$7.2B
Total invested
$78.2M
Avg. check
37
Industries
Biotechnology 16Therapeutics 11Health Care 9Medical 5Life Science 5Pharmaceutical 4+31 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 104
Laronde
August 2021

Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.

Biotechnology · Cambridge$440.0M Series B
Abata Therapeutics
August 2024

Abata Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases including progressive multiple sclerosis.

Biotechnology · CambridgeCorporate Round
Amount
August 2024

Amount is a digital technology company that accelerates digital transformation for financial institutions.

Banking · Chicago$30.0M Venture - Series Unknown
Finastra
August 2023

Finastra provides the broadest portfolio of financial services software.

Financial Services · Paddington$5.3B Debt Financing
FireHydrant
August 2021

FireHydrant is an incident management tool that helps companies recover from IT disasters more quickly.

Data Center Automation · New York$23.0M Series B
BRIUS
July 2026

BRIUS is a healthcare company that focuses in the orthodontics and medical device industry.

Health Care · Carrollton$5.0M Venture - Series Unknown
Pretzel Therapeutics
July 2025

Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.

Biotechnology · WalthamVenture - Series Unknown
Erasca
July 2026

Erasca is a developer of oncology drugs intended to provide precision oncology options.

Biotechnology · San Diego$632.5M Post-IPO Equity
City Therapeutics
June 2026

City Therapeutics is a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines for a range of diseases.

Biopharma · Cambridge$99.5M Series B
Viseon
June 2024

Viseon is a privately held medical device company committed to developing proprietary technology.

Biotechnology · IrvineUndisclosed
Engine Biosciences
June 2026

Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.

Artificial Intelligence (AI) · SingaporeVenture - Series Unknown
Averna Therapeutics
June 2024

Averna Therapeutics develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.

Biotechnology · Boston$85.0M Series A
Osanni Bio
June 2026

Osanni Bio is a biotechnology company developing therapies aimed at preventing and reversing blindness caused by retinal diseases.

Biotechnology · San Francisco$190.0M Series B
One Biosciences
June 2026

One Biosciences leverages single-cell technologies to identify new therapeutics for difficult-to-treat diseases.

Biotechnology · ParisGrant
HappyVore
June 2022

HappyVore cultivates a passion for taste, the real, the healthy, and the impact on the planet.

Agriculture · Paris$36.9M Venture - Series Unknown
Morphic Therapeutic
May 2023

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

Biotechnology · Waltham$276.0M Post-IPO Equity
Cartesian Therapeutics
May 2026

Pioneering Potent, Safer Cell Therapy in and Beyond Oncology

Biotechnology · Gaithersburg$50.0M Post-IPO Debt
Cyclerion Therapeutics
May 2023

Cyclerion Therapeutics harnesses the potential of soluble guanylate cyclase (sGC) pharmacology.

Biotechnology · Cambridge$5.0M Post-IPO Equity
Ikena Oncology
May 2023

Ikena Oncology develops differentiated therapies to target cancer growth and resistance, focusing on Hippo and RAS signaling pathways.

Biotechnology · Boston$40.0M Post-IPO Equity
ITeos Therapeutics
May 2024

ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.

Biotechnology · Cambridge$120.0M Post-IPO Equity
VeraDermics
April 2026

VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions.

Health Care · New Haven$384.4M Post-IPO Equity
Ring Therapeutics
March 2023

Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.

Biotechnology · Cambridge$86.5M Series C
Flare Therapeutics
March 2023

Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.

Biopharma · Cambridge$123.0M Series B
Learn In
March 2022

Learn In is an upskilling-as-a-service platform that connects employers and learners.

EdTech · San Francisco$10.0M Series A

Where Invus invests

Biotechnology16
Therapeutics11
Health Care9
Medical5
Life Science5
Pharmaceutical4

About Invus's portfolio

How many companies has Invus invested in?

Invus has invested in 104 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Invus invest in?

Invus's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 37 different industry categories.

What is Invus's largest investment?

Among tracked funding rounds, Finastra received $5.3B in a Debt Financing round. Invus's total known invested capital is $7.2B.

What is the average investment size for Invus?

Invus's average investment size is $78.2M across its portfolio of 104 companies.

What are Invus's most recent investments?

Recent Invus portfolio additions include Laronde, Abata Therapeutics, Amount, Finastra, FireHydrant. These companies were founded in 2020 or later.

Reach the founders behind these 104 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →